vs
Side-by-side financial comparison of BADGER METER INC (BMI) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $234.1M, roughly 1.2× BADGER METER INC). BADGER METER INC runs the higher net margin — 14.3% vs -45.7%, a 60.0% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 14.1%). BADGER METER INC produced more free cash flow last quarter ($50.8M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 9.2%).
Badger Meter Inc. is a leading global provider of flow measurement and control solutions, serving water utilities, industrial, commercial, and residential customer segments. Its core offerings include smart water meters, IoT-enabled usage monitoring systems, and supporting software that help clients track resource consumption, cut waste, and boost operational efficiency, with key markets spanning North America, Europe, and the Asia-Pacific region.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
BMI vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $234.1M | $281.3M |
| Net Profit | $33.6M | $-128.5M |
| Gross Margin | 39.7% | 64.6% |
| Operating Margin | 18.4% | -43.0% |
| Net Margin | 14.3% | -45.7% |
| Revenue YoY | 14.1% | 39.4% |
| Net Profit YoY | 9.3% | -15.8% |
| EPS (diluted) | $1.13 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $234.1M | $281.3M | ||
| Q3 25 | $222.2M | $265.2M | ||
| Q2 25 | $238.1M | $232.1M | ||
| Q1 25 | $222.2M | $203.5M | ||
| Q4 24 | $205.2M | $201.8M | ||
| Q3 24 | $208.4M | $191.5M | ||
| Q2 24 | $216.7M | $177.2M | ||
| Q1 24 | $196.3M | $168.5M |
| Q4 25 | $33.6M | $-128.5M | ||
| Q3 25 | $35.1M | $-92.7M | ||
| Q2 25 | $34.6M | $-99.9M | ||
| Q1 25 | $38.4M | $-95.2M | ||
| Q4 24 | $30.7M | $-111.0M | ||
| Q3 24 | $32.0M | $-107.8M | ||
| Q2 24 | $33.1M | $-102.6M | ||
| Q1 24 | $29.1M | $-115.0M |
| Q4 25 | 39.7% | 64.6% | ||
| Q3 25 | 43.1% | 64.7% | ||
| Q2 25 | 41.1% | 65.0% | ||
| Q1 25 | 42.9% | 63.3% | ||
| Q4 24 | 40.3% | 61.6% | ||
| Q3 24 | 40.2% | 61.1% | ||
| Q2 24 | 39.4% | 59.1% | ||
| Q1 24 | 39.3% | 61.2% |
| Q4 25 | 18.4% | -43.0% | ||
| Q3 25 | 20.7% | -37.3% | ||
| Q2 25 | 18.8% | -45.9% | ||
| Q1 25 | 22.2% | -54.6% | ||
| Q4 24 | 19.1% | -62.4% | ||
| Q3 24 | 19.5% | -61.3% | ||
| Q2 24 | 19.2% | -56.8% | ||
| Q1 24 | 18.6% | -59.2% |
| Q4 25 | 14.3% | -45.7% | ||
| Q3 25 | 15.8% | -35.0% | ||
| Q2 25 | 14.5% | -43.0% | ||
| Q1 25 | 17.3% | -46.8% | ||
| Q4 24 | 15.0% | -55.0% | ||
| Q3 24 | 15.4% | -56.3% | ||
| Q2 24 | 15.3% | -57.9% | ||
| Q1 24 | 14.8% | -68.2% |
| Q4 25 | $1.13 | $-1.01 | ||
| Q3 25 | $1.19 | $-0.74 | ||
| Q2 25 | $1.17 | $-0.80 | ||
| Q1 25 | $1.30 | $-0.77 | ||
| Q4 24 | $1.04 | $-0.90 | ||
| Q3 24 | $1.08 | $-0.88 | ||
| Q2 24 | $1.12 | $-0.84 | ||
| Q1 24 | $0.99 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $378.2M |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $713.3M | $-99.3M |
| Total Assets | $973.6M | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $378.2M | ||
| Q3 25 | — | $580.0M | ||
| Q2 25 | — | $629.1M | ||
| Q1 25 | — | $698.6M | ||
| Q4 24 | — | $525.5M | ||
| Q3 24 | — | $585.0M | ||
| Q2 24 | — | $933.7M | ||
| Q1 24 | — | $1.0B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $713.3M | $-99.3M | ||
| Q3 25 | $702.5M | $-354.5M | ||
| Q2 25 | $677.6M | $-305.5M | ||
| Q1 25 | $641.7M | $-250.8M | ||
| Q4 24 | $606.2M | $-139.6M | ||
| Q3 24 | $591.2M | $-60.1M | ||
| Q2 24 | $563.1M | $-1.6M | ||
| Q1 24 | $535.6M | $68.3M |
| Q4 25 | $973.6M | $2.0B | ||
| Q3 25 | $978.3M | $1.3B | ||
| Q2 25 | $936.4M | $1.3B | ||
| Q1 25 | $899.6M | $1.3B | ||
| Q4 24 | $816.4M | $1.5B | ||
| Q3 24 | $802.9M | $1.5B | ||
| Q2 24 | $781.3M | $1.6B | ||
| Q1 24 | $743.5M | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $54.8M | $-26.4M |
| Free Cash FlowOCF − Capex | $50.8M | $-54.2M |
| FCF MarginFCF / Revenue | 21.7% | -19.3% |
| Capex IntensityCapex / Revenue | 1.7% | 9.9% |
| Cash ConversionOCF / Net Profit | 1.63× | — |
| TTM Free Cash FlowTrailing 4 quarters | $169.7M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $54.8M | $-26.4M | ||
| Q3 25 | $51.3M | $-35.4M | ||
| Q2 25 | $44.6M | $-60.3M | ||
| Q1 25 | $33.0M | $-62.7M | ||
| Q4 24 | $52.1M | $-64.5M | ||
| Q3 24 | $45.1M | $-51.1M | ||
| Q2 24 | $36.4M | $-94.0M | ||
| Q1 24 | $21.5M | $-30.3M |
| Q4 25 | $50.8M | $-54.2M | ||
| Q3 25 | $48.2M | $-45.8M | ||
| Q2 25 | $40.6M | $-65.9M | ||
| Q1 25 | $30.1M | $-67.1M | ||
| Q4 24 | $47.4M | $-83.4M | ||
| Q3 24 | $42.0M | $-55.3M | ||
| Q2 24 | $34.1M | $-99.1M | ||
| Q1 24 | $18.8M | $-37.2M |
| Q4 25 | 21.7% | -19.3% | ||
| Q3 25 | 21.7% | -17.3% | ||
| Q2 25 | 17.1% | -28.4% | ||
| Q1 25 | 13.5% | -33.0% | ||
| Q4 24 | 23.1% | -41.3% | ||
| Q3 24 | 20.1% | -28.9% | ||
| Q2 24 | 15.7% | -55.9% | ||
| Q1 24 | 9.6% | -22.1% |
| Q4 25 | 1.7% | 9.9% | ||
| Q3 25 | 1.4% | 3.9% | ||
| Q2 25 | 1.7% | 2.4% | ||
| Q1 25 | 1.3% | 2.2% | ||
| Q4 24 | 2.3% | 9.4% | ||
| Q3 24 | 1.5% | 2.2% | ||
| Q2 24 | 1.1% | 2.9% | ||
| Q1 24 | 1.4% | 4.1% |
| Q4 25 | 1.63× | — | ||
| Q3 25 | 1.46× | — | ||
| Q2 25 | 1.29× | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | 1.70× | — | ||
| Q3 24 | 1.41× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | 0.74× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BMI
| Transferred At Point In Time | $198.6M | 85% |
| Transferred Over Time | $22.1M | 9% |
| Other | $13.4M | 6% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
